VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q2 2021
Holdings as of Jun 30, 2021, filed Aug 13, 2021. Long positions only; changes compare share counts with Q1 2021.
- Positions
- 29
- +1 vs. Q1 2021
- Portfolio value
- $824.4M
- −$97.4M (−10.6%) vs. Q1 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | COM | 19,495 | $357.0K | <0.1% | 00.0% | Unchanged | History |
| ACETAdicet Bio, Inc. | COM | 183,702 | $1.89M | 0.2% | −816,298−81.6% | Reduced | History |
| Catabasis Pharmaceuticals IN14875P206 | COM NEW | 3,234,000 | $6.82M | 0.8% | +3,234,000 | New | – |
| HARPHarpoon Therapeutics, Inc. | COM | 512,005 | $7.10M | 0.9% | +512,005 | New | History |
| AKYAAkoya Biosciences, Inc. | COM | 400,000 | $7.74M | 0.9% | +400,000 | New | History |
| ALGSAligos Therapeutics, Inc. | COM | 408,377 | $8.32M | 1.0% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 1,088,817 | $8.83M | 1.1% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 272,306 | $11.6M | 1.4% | −100,000−26.9% | Reduced | History |
| KURAKura Oncology, Inc. | COM | 575,000 | $12.0M | 1.5% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 391,000 | $12.4M | 1.5% | +391,000 | New | History |
| LONALeonaBio, Inc. | COM | 1,485,005 | $15.2M | 1.8% | −206,618−12.2% | Reduced | History |
| PHVSPharvaris N.V. | COM | 902,882 | $16.8M | 2.0% | 00.0% | Unchanged | History |
| CVRXCVRx, Inc. | COM | 633,370 | $17.7M | 2.2% | +633,370 | New | History |
| EPIXESSA Pharma Inc. | COM NEW | 625,754 | $17.9M | 2.2% | 00.0% | Unchanged | History |
| Trillium Therapeutics Inc.89620X506 | COM NEW | 2,001,686 | $19.4M | 2.4% | −2,038,314−50.5% | Reduced | – |
| PRVBProvention Bio, Inc. | COM | 2,902,744 | $24.5M | 3.0% | +2,902,744 | New | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,127,272 | $25.0M | 3.0% | +1,127,272 | New | History |
| CGEMCullinan Therapeutics, Inc. | COM | 976,145 | $25.1M | 3.0% | −200,000−17.0% | Reduced | History |
| GHRSGH Research PLC | ORDINARY SHARES | 1,275,831 | $27.7M | 3.4% | +1,275,831 | New | History |
| KNTEKinnate Biopharma Inc. | COM | 1,473,014 | $34.3M | 4.2% | 00.0% | Unchanged | History |
| ALTAltimmune, Inc. | COM NEW | 3,500,000 | $34.5M | 4.2% | 00.0% | Unchanged | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,240,610 | $41.5M | 5.0% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 1,536,193 | $43.0M | 5.2% | 00.0% | Unchanged | History |
| RLMDRelmada Therapeutics, Inc. | COM | 1,387,720 | $44.4M | 5.4% | +534,514+62.6% | Added | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 2,641,809 | $47.4M | 5.7% | 00.0% | Unchanged | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,612,617 | $49.6M | 6.0% | +1,612,617 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 16,047,286 | $50.5M | 6.1% | −255,310−1.6% | Reduced | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $80.1M | 9.7% | +843,380+22.7% | Added | History |
| TILInstil Bio, Inc. | COM | 6,865,076 | $132.6M | 16.1% | 00.0% | Unchanged | History |
Sold out since Q1 2021 (8)
Positions held at the end of Q1 2021 that are gone from this filing.
| Security | Class | Shares in Q1 2021 | Value in Q1 2021 | % of portfolio in Q1 2021 | History |
|---|---|---|---|---|---|
| CNSTConstellation Pharmaceuticals Inc | COM | 4,016,873 | $94.0M | 10.2% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 591,782 | $13.2M | 1.4% | History |
| APTOAptose Biosciences Inc. | COM NEW | 1,605,400 | $9.59M | 1.0% | History |
| EYPTEyePoint, Inc. | COM NEW | 700,000 | $7.11M | 0.8% | History |
| BCTG Acquisition Corp05492W103 | COM | 500,000 | $5.56M | 0.6% | – |
| MTCRMetacrine, Inc. | COM | 680,000 | $4.22M | 0.5% | History |
| SPRYARS Pharmaceuticals, Inc. | COM | 85,000 | $3.71M | 0.4% | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 120,649 | $2.45M | 0.3% | History |